nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—Corneal deposits—Vandetanib—thyroid cancer	0.0481	0.119	CcSEcCtD
Olopatadine—S100A1—neck—thyroid cancer	0.0411	0.105	CbGeAlD
Olopatadine—S100A13—neck—thyroid cancer	0.0365	0.0936	CbGeAlD
Olopatadine—S100A2—saliva-secreting gland—thyroid cancer	0.0348	0.0893	CbGeAlD
Olopatadine—S100A1—saliva-secreting gland—thyroid cancer	0.0321	0.0823	CbGeAlD
Olopatadine—S100A2—trachea—thyroid cancer	0.0269	0.0689	CbGeAlD
Olopatadine—S100A12—Advanced glycosylation endproduct receptor signaling—LGALS3—thyroid cancer	0.0264	0.127	CbGpPWpGaD
Olopatadine—S100B—Advanced glycosylation endproduct receptor signaling—LGALS3—thyroid cancer	0.025	0.12	CbGpPWpGaD
Olopatadine—S100A1—trachea—thyroid cancer	0.0248	0.0635	CbGeAlD
Olopatadine—S100A2—thyroid gland—thyroid cancer	0.0213	0.0545	CbGeAlD
Olopatadine—S100A1—thyroid gland—thyroid cancer	0.0196	0.0502	CbGeAlD
Olopatadine—S100A2—head—thyroid cancer	0.0189	0.0484	CbGeAlD
Olopatadine—S100A13—thyroid gland—thyroid cancer	0.0174	0.0445	CbGeAlD
Olopatadine—S100A1—head—thyroid cancer	0.0174	0.0445	CbGeAlD
Olopatadine—S100A13—head—thyroid cancer	0.0154	0.0395	CbGeAlD
Olopatadine—S100A12—head—thyroid cancer	0.0152	0.039	CbGeAlD
Olopatadine—S100B—head—thyroid cancer	0.015	0.0385	CbGeAlD
Olopatadine—Visual acuity reduced—Vandetanib—thyroid cancer	0.0148	0.0367	CcSEcCtD
Olopatadine—S100A1—lymph node—thyroid cancer	0.0122	0.0312	CbGeAlD
Olopatadine—S100A2—p73 transcription factor network—CDK1—thyroid cancer	0.012	0.0578	CbGpPWpGaD
Olopatadine—S100A13—lymph node—thyroid cancer	0.0108	0.0277	CbGeAlD
Olopatadine—S100A12—lymph node—thyroid cancer	0.0106	0.0273	CbGeAlD
Olopatadine—S100B—lymph node—thyroid cancer	0.0105	0.0269	CbGeAlD
Olopatadine—Dry eye—Vandetanib—thyroid cancer	0.00811	0.0202	CcSEcCtD
Olopatadine—Dry skin—Vandetanib—thyroid cancer	0.00584	0.0145	CcSEcCtD
Olopatadine—Nasopharyngitis—Vandetanib—thyroid cancer	0.0057	0.0142	CcSEcCtD
Olopatadine—S100B—Nuclear signaling by ERBB4—NRG1—thyroid cancer	0.00569	0.0274	CbGpPWpGaD
Olopatadine—Influenza—Vandetanib—thyroid cancer	0.00551	0.0137	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00512	0.0127	CcSEcCtD
Olopatadine—Infestation—Vandetanib—thyroid cancer	0.00491	0.0122	CcSEcCtD
Olopatadine—Infestation NOS—Vandetanib—thyroid cancer	0.00491	0.0122	CcSEcCtD
Olopatadine—Depression—Vandetanib—thyroid cancer	0.0049	0.0122	CcSEcCtD
Olopatadine—Conjunctivitis—Vandetanib—thyroid cancer	0.00477	0.0119	CcSEcCtD
Olopatadine—Urinary tract infection—Vandetanib—thyroid cancer	0.00477	0.0119	CcSEcCtD
Olopatadine—Epistaxis—Vandetanib—thyroid cancer	0.00463	0.0115	CcSEcCtD
Olopatadine—Sinusitis—Vandetanib—thyroid cancer	0.00461	0.0115	CcSEcCtD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—CDK1—thyroid cancer	0.00444	0.0214	CbGpPWpGaD
Olopatadine—HRH1—trachea—thyroid cancer	0.00439	0.0112	CbGeAlD
Olopatadine—Visual impairment—Vandetanib—thyroid cancer	0.00425	0.0106	CcSEcCtD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—CDK1—thyroid cancer	0.0042	0.0202	CbGpPWpGaD
Olopatadine—Eye disorder—Vandetanib—thyroid cancer	0.00412	0.0102	CcSEcCtD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNA2—thyroid cancer	0.00406	0.0195	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—CDK1—thyroid cancer	0.00402	0.0193	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—CDK1—thyroid cancer	0.00398	0.0192	CbGpPWpGaD
Olopatadine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00397	0.00988	CcSEcCtD
Olopatadine—Dry skin—Sorafenib—thyroid cancer	0.00394	0.00979	CcSEcCtD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—CDK1—thyroid cancer	0.00391	0.0188	CbGpPWpGaD
Olopatadine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00384	0.00956	CcSEcCtD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNA2—thyroid cancer	0.00384	0.0185	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—CDK1—thyroid cancer	0.0038	0.0183	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—CDK1—thyroid cancer	0.00377	0.0182	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—CDK1—thyroid cancer	0.00376	0.0181	CbGpPWpGaD
Olopatadine—Dysgeusia—Vandetanib—thyroid cancer	0.00376	0.00934	CcSEcCtD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—CDK1—thyroid cancer	0.00371	0.0178	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—CDK1—thyroid cancer	0.0037	0.0178	CbGpPWpGaD
Olopatadine—Muscle spasms—Vandetanib—thyroid cancer	0.00369	0.00917	CcSEcCtD
Olopatadine—Vision blurred—Vandetanib—thyroid cancer	0.00362	0.00899	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—CDK1—thyroid cancer	0.00357	0.0172	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—CDK1—thyroid cancer	0.00356	0.0171	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—CDK1—thyroid cancer	0.00351	0.0169	CbGpPWpGaD
Olopatadine—Keratitis—Epirubicin—thyroid cancer	0.00337	0.00839	CcSEcCtD
Olopatadine—S100B—MyD88-independent cascade—CDK1—thyroid cancer	0.00336	0.0162	CbGpPWpGaD
Olopatadine—Cough—Vandetanib—thyroid cancer	0.00335	0.00832	CcSEcCtD
Olopatadine—Infestation NOS—Sorafenib—thyroid cancer	0.00331	0.00823	CcSEcCtD
Olopatadine—Infestation—Sorafenib—thyroid cancer	0.00331	0.00823	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00324	0.00807	CcSEcCtD
Olopatadine—S100A12—Activated TLR4 signalling—CDK1—thyroid cancer	0.0032	0.0154	CbGpPWpGaD
Olopatadine—Dry mouth—Vandetanib—thyroid cancer	0.0032	0.00794	CcSEcCtD
Olopatadine—Oedema—Vandetanib—thyroid cancer	0.00313	0.00779	CcSEcCtD
Olopatadine—Epistaxis—Sorafenib—thyroid cancer	0.00312	0.00777	CcSEcCtD
Olopatadine—Keratitis—Doxorubicin—thyroid cancer	0.00312	0.00776	CcSEcCtD
Olopatadine—Infection—Vandetanib—thyroid cancer	0.00311	0.00773	CcSEcCtD
Olopatadine—HRH1—head—thyroid cancer	0.00308	0.00789	CbGeAlD
Olopatadine—Nervous system disorder—Vandetanib—thyroid cancer	0.00307	0.00764	CcSEcCtD
Olopatadine—S100A2—Direct p53 effectors—PTEN—thyroid cancer	0.00305	0.0147	CbGpPWpGaD
Olopatadine—Skin disorder—Vandetanib—thyroid cancer	0.00304	0.00756	CcSEcCtD
Olopatadine—S100B—Activated TLR4 signalling—CDK1—thyroid cancer	0.00303	0.0146	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—CDK1—thyroid cancer	0.00301	0.0145	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—CDK1—thyroid cancer	0.00285	0.0137	CbGpPWpGaD
Olopatadine—Dyspnoea—Vandetanib—thyroid cancer	0.00279	0.00694	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0027	0.00672	CcSEcCtD
Olopatadine—Stinging—Epirubicin—thyroid cancer	0.0027	0.00672	CcSEcCtD
Olopatadine—Fatigue—Vandetanib—thyroid cancer	0.0027	0.00671	CcSEcCtD
Olopatadine—Immune system disorder—Sorafenib—thyroid cancer	0.00269	0.00668	CcSEcCtD
Olopatadine—S100A12—Toll-Like Receptors Cascades—CDK1—thyroid cancer	0.00268	0.0129	CbGpPWpGaD
Olopatadine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00268	0.00666	CcSEcCtD
Olopatadine—Pain—Vandetanib—thyroid cancer	0.00268	0.00666	CcSEcCtD
Olopatadine—Erythema—Sorafenib—thyroid cancer	0.00259	0.00644	CcSEcCtD
Olopatadine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00256	0.00637	CcSEcCtD
Olopatadine—Dysgeusia—Sorafenib—thyroid cancer	0.00254	0.0063	CcSEcCtD
Olopatadine—S100B—Toll-Like Receptors Cascades—CDK1—thyroid cancer	0.00253	0.0122	CbGpPWpGaD
Olopatadine—Stinging—Doxorubicin—thyroid cancer	0.0025	0.00621	CcSEcCtD
Olopatadine—Muscle spasms—Sorafenib—thyroid cancer	0.00249	0.00619	CcSEcCtD
Olopatadine—Abdominal pain—Vandetanib—thyroid cancer	0.00248	0.00615	CcSEcCtD
Olopatadine—Body temperature increased—Vandetanib—thyroid cancer	0.00248	0.00615	CcSEcCtD
Olopatadine—Cough increased—Epirubicin—thyroid cancer	0.00239	0.00594	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—CDK1—thyroid cancer	0.00239	0.0115	CbGpPWpGaD
Olopatadine—Lacrimation increased—Epirubicin—thyroid cancer	0.00237	0.0059	CcSEcCtD
Olopatadine—Ulcer—Epirubicin—thyroid cancer	0.00231	0.00575	CcSEcCtD
Olopatadine—Cough—Sorafenib—thyroid cancer	0.00226	0.00562	CcSEcCtD
Olopatadine—Asthenia—Vandetanib—thyroid cancer	0.00225	0.00559	CcSEcCtD
Olopatadine—Pruritus—Vandetanib—thyroid cancer	0.00222	0.00551	CcSEcCtD
Olopatadine—Cough increased—Doxorubicin—thyroid cancer	0.00221	0.0055	CcSEcCtD
Olopatadine—Lacrimation increased—Doxorubicin—thyroid cancer	0.0022	0.00546	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00219	0.00544	CcSEcCtD
Olopatadine—Dermatitis contact—Epirubicin—thyroid cancer	0.00216	0.00538	CcSEcCtD
Olopatadine—Dry mouth—Sorafenib—thyroid cancer	0.00216	0.00536	CcSEcCtD
Olopatadine—HRH1—lymph node—thyroid cancer	0.00215	0.00553	CbGeAlD
Olopatadine—Diarrhoea—Vandetanib—thyroid cancer	0.00214	0.00533	CcSEcCtD
Olopatadine—Ulcer—Doxorubicin—thyroid cancer	0.00214	0.00532	CcSEcCtD
Olopatadine—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00212	0.0102	CbGpPWpGaD
Olopatadine—Infection—Sorafenib—thyroid cancer	0.0021	0.00522	CcSEcCtD
Olopatadine—S100A2—Direct p53 effectors—TP53—thyroid cancer	0.00208	0.01	CbGpPWpGaD
Olopatadine—Nervous system disorder—Sorafenib—thyroid cancer	0.00207	0.00515	CcSEcCtD
Olopatadine—Dizziness—Vandetanib—thyroid cancer	0.00207	0.00515	CcSEcCtD
Olopatadine—Skin disorder—Sorafenib—thyroid cancer	0.00205	0.0051	CcSEcCtD
Olopatadine—Dry eye—Epirubicin—thyroid cancer	0.00202	0.00502	CcSEcCtD
Olopatadine—Dermatitis contact—Doxorubicin—thyroid cancer	0.002	0.00497	CcSEcCtD
Olopatadine—Vomiting—Vandetanib—thyroid cancer	0.00199	0.00495	CcSEcCtD
Olopatadine—Rash—Vandetanib—thyroid cancer	0.00197	0.00491	CcSEcCtD
Olopatadine—Dermatitis—Vandetanib—thyroid cancer	0.00197	0.0049	CcSEcCtD
Olopatadine—Headache—Vandetanib—thyroid cancer	0.00196	0.00488	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—NRG1—thyroid cancer	0.00192	0.00922	CbGpPWpGaD
Olopatadine—Dyspnoea—Sorafenib—thyroid cancer	0.00188	0.00468	CcSEcCtD
Olopatadine—Dry eye—Doxorubicin—thyroid cancer	0.00187	0.00465	CcSEcCtD
Olopatadine—Nausea—Vandetanib—thyroid cancer	0.00186	0.00462	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00182	0.00453	CcSEcCtD
Olopatadine—Fatigue—Sorafenib—thyroid cancer	0.00182	0.00453	CcSEcCtD
Olopatadine—Pain—Sorafenib—thyroid cancer	0.00181	0.00449	CcSEcCtD
Olopatadine—Eye pain—Epirubicin—thyroid cancer	0.00176	0.00437	CcSEcCtD
Olopatadine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00173	0.00429	CcSEcCtD
Olopatadine—Abdominal pain—Sorafenib—thyroid cancer	0.00167	0.00415	CcSEcCtD
Olopatadine—Body temperature increased—Sorafenib—thyroid cancer	0.00167	0.00415	CcSEcCtD
Olopatadine—Eye pain—Doxorubicin—thyroid cancer	0.00163	0.00405	CcSEcCtD
Olopatadine—Hypersensitivity—Sorafenib—thyroid cancer	0.00156	0.00387	CcSEcCtD
Olopatadine—Asthenia—Sorafenib—thyroid cancer	0.00152	0.00377	CcSEcCtD
Olopatadine—Pruritus—Sorafenib—thyroid cancer	0.00149	0.00372	CcSEcCtD
Olopatadine—Dry skin—Epirubicin—thyroid cancer	0.00146	0.00362	CcSEcCtD
Olopatadine—Diarrhoea—Sorafenib—thyroid cancer	0.00145	0.00359	CcSEcCtD
Olopatadine—Nasopharyngitis—Epirubicin—thyroid cancer	0.00142	0.00353	CcSEcCtD
Olopatadine—Dizziness—Sorafenib—thyroid cancer	0.0014	0.00347	CcSEcCtD
Olopatadine—Influenza—Epirubicin—thyroid cancer	0.00137	0.00341	CcSEcCtD
Olopatadine—Dry skin—Doxorubicin—thyroid cancer	0.00135	0.00335	CcSEcCtD
Olopatadine—Vomiting—Sorafenib—thyroid cancer	0.00134	0.00334	CcSEcCtD
Olopatadine—Rash—Sorafenib—thyroid cancer	0.00133	0.00331	CcSEcCtD
Olopatadine—Dermatitis—Sorafenib—thyroid cancer	0.00133	0.00331	CcSEcCtD
Olopatadine—Headache—Sorafenib—thyroid cancer	0.00132	0.00329	CcSEcCtD
Olopatadine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00131	0.00327	CcSEcCtD
Olopatadine—S100A12—Immune System—RAP1GAP—thyroid cancer	0.0013	0.00626	CbGpPWpGaD
Olopatadine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00128	0.00317	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—LGALS3—thyroid cancer	0.00127	0.00612	CbGpPWpGaD
Olopatadine—Influenza—Doxorubicin—thyroid cancer	0.00127	0.00316	CcSEcCtD
Olopatadine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00127	0.00611	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PRKAR1A—thyroid cancer	0.00126	0.00607	CbGpPWpGaD
Olopatadine—Nausea—Sorafenib—thyroid cancer	0.00125	0.00312	CcSEcCtD
Olopatadine—Weight increased—Epirubicin—thyroid cancer	0.00125	0.00311	CcSEcCtD
Olopatadine—S100B—Immune System—RAP1GAP—thyroid cancer	0.00123	0.00592	CbGpPWpGaD
Olopatadine—Infestation NOS—Epirubicin—thyroid cancer	0.00122	0.00304	CcSEcCtD
Olopatadine—Infestation—Epirubicin—thyroid cancer	0.00122	0.00304	CcSEcCtD
Olopatadine—S100B—Innate Immune System—LGALS3—thyroid cancer	0.0012	0.00579	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PRKAR1A—thyroid cancer	0.00119	0.00574	CbGpPWpGaD
Olopatadine—Conjunctivitis—Epirubicin—thyroid cancer	0.00119	0.00296	CcSEcCtD
Olopatadine—Urinary tract infection—Epirubicin—thyroid cancer	0.00119	0.00296	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00118	0.00294	CcSEcCtD
Olopatadine—Weight increased—Doxorubicin—thyroid cancer	0.00116	0.00287	CcSEcCtD
Olopatadine—Epistaxis—Epirubicin—thyroid cancer	0.00115	0.00287	CcSEcCtD
Olopatadine—Sinusitis—Epirubicin—thyroid cancer	0.00115	0.00286	CcSEcCtD
Olopatadine—Infestation NOS—Doxorubicin—thyroid cancer	0.00113	0.00282	CcSEcCtD
Olopatadine—Infestation—Doxorubicin—thyroid cancer	0.00113	0.00282	CcSEcCtD
Olopatadine—Rhinitis—Epirubicin—thyroid cancer	0.0011	0.00274	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—thyroid cancer	0.0011	0.00274	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—thyroid cancer	0.0011	0.00274	CcSEcCtD
Olopatadine—Hypoaesthesia—Epirubicin—thyroid cancer	0.00109	0.00272	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—thyroid cancer	0.00109	0.00271	CcSEcCtD
Olopatadine—Epistaxis—Doxorubicin—thyroid cancer	0.00107	0.00266	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—thyroid cancer	0.00106	0.00264	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—thyroid cancer	0.00106	0.00263	CcSEcCtD
Olopatadine—Eye disorder—Epirubicin—thyroid cancer	0.00103	0.00255	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—thyroid cancer	0.00102	0.00253	CcSEcCtD
Olopatadine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00101	0.00252	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—thyroid cancer	0.00101	0.00251	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—thyroid cancer	0.000993	0.00247	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000991	0.00246	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—CALCB—thyroid cancer	0.000986	0.00474	CbGpPWpGaD
Olopatadine—Visual impairment—Doxorubicin—thyroid cancer	0.00098	0.00244	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—PTEN—thyroid cancer	0.00096	0.00462	CbGpPWpGaD
Olopatadine—Erythema—Epirubicin—thyroid cancer	0.000957	0.00238	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—thyroid cancer	0.00095	0.00236	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—thyroid cancer	0.000937	0.00233	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—TRIM33—thyroid cancer	0.000934	0.0045	CbGpPWpGaD
Olopatadine—Back pain—Epirubicin—thyroid cancer	0.000925	0.0023	CcSEcCtD
Olopatadine—Muscle spasms—Epirubicin—thyroid cancer	0.00092	0.00229	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—thyroid cancer	0.000919	0.00228	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000916	0.00228	CcSEcCtD
Olopatadine—HRH1—GPCR ligand binding—CALCB—thyroid cancer	0.000908	0.00437	CbGpPWpGaD
Olopatadine—Vision blurred—Epirubicin—thyroid cancer	0.000902	0.00224	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000888	0.00221	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—thyroid cancer	0.000885	0.0022	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CDK1—thyroid cancer	0.000868	0.00418	CbGpPWpGaD
Olopatadine—Dysgeusia—Doxorubicin—thyroid cancer	0.000867	0.00215	CcSEcCtD
Olopatadine—Malaise—Epirubicin—thyroid cancer	0.000863	0.00214	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—thyroid cancer	0.000856	0.00213	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—NRAS—thyroid cancer	0.000856	0.00412	CbGpPWpGaD
Olopatadine—Muscle spasms—Doxorubicin—thyroid cancer	0.000851	0.00212	CcSEcCtD
Olopatadine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000836	0.00402	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IFNA2—thyroid cancer	0.000835	0.00402	CbGpPWpGaD
Olopatadine—Cough—Epirubicin—thyroid cancer	0.000835	0.00208	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—thyroid cancer	0.000834	0.00207	CcSEcCtD
Olopatadine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000821	0.00204	CcSEcCtD
Olopatadine—S100B—Innate Immune System—CDK1—thyroid cancer	0.000821	0.00395	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000809	0.00201	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—thyroid cancer	0.000805	0.002	CcSEcCtD
Olopatadine—Malaise—Doxorubicin—thyroid cancer	0.000798	0.00198	CcSEcCtD
Olopatadine—Dry mouth—Epirubicin—thyroid cancer	0.000797	0.00198	CcSEcCtD
Olopatadine—S100B—Innate Immune System—IFNA2—thyroid cancer	0.00079	0.0038	CbGpPWpGaD
Olopatadine—Oedema—Epirubicin—thyroid cancer	0.000781	0.00194	CcSEcCtD
Olopatadine—Infection—Epirubicin—thyroid cancer	0.000776	0.00193	CcSEcCtD
Olopatadine—Cough—Doxorubicin—thyroid cancer	0.000772	0.00192	CcSEcCtD
Olopatadine—Nervous system disorder—Epirubicin—thyroid cancer	0.000766	0.0019	CcSEcCtD
Olopatadine—Skin disorder—Epirubicin—thyroid cancer	0.000758	0.00189	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000748	0.00186	CcSEcCtD
Olopatadine—S100A12—Immune System—TPR—thyroid cancer	0.000746	0.00359	CbGpPWpGaD
Olopatadine—Discomfort—Doxorubicin—thyroid cancer	0.000745	0.00185	CcSEcCtD
Olopatadine—S100A12—Immune System—LGALS3—thyroid cancer	0.00074	0.00356	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000737	0.00355	CbGpPWpGaD
Olopatadine—Dry mouth—Doxorubicin—thyroid cancer	0.000737	0.00183	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—KRAS—thyroid cancer	0.000737	0.00355	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PRKAR1A—thyroid cancer	0.000734	0.00353	CbGpPWpGaD
Olopatadine—Oedema—Doxorubicin—thyroid cancer	0.000722	0.0018	CcSEcCtD
Olopatadine—Infection—Doxorubicin—thyroid cancer	0.000718	0.00178	CcSEcCtD
Olopatadine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000709	0.00176	CcSEcCtD
Olopatadine—S100B—Immune System—TPR—thyroid cancer	0.000706	0.0034	CbGpPWpGaD
Olopatadine—Skin disorder—Doxorubicin—thyroid cancer	0.000702	0.00174	CcSEcCtD
Olopatadine—S100B—Immune System—LGALS3—thyroid cancer	0.0007	0.00337	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NRG1—thyroid cancer	0.000697	0.00336	CbGpPWpGaD
Olopatadine—Dyspnoea—Epirubicin—thyroid cancer	0.000696	0.00173	CcSEcCtD
Olopatadine—S100B—Immune System—PRKAR1A—thyroid cancer	0.000694	0.00334	CbGpPWpGaD
Olopatadine—Somnolence—Epirubicin—thyroid cancer	0.000694	0.00173	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000674	0.00168	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—thyroid cancer	0.000673	0.00167	CcSEcCtD
Olopatadine—Pain—Epirubicin—thyroid cancer	0.000668	0.00166	CcSEcCtD
Olopatadine—S100B—Innate Immune System—NRG1—thyroid cancer	0.000659	0.00317	CbGpPWpGaD
Olopatadine—Dyspnoea—Doxorubicin—thyroid cancer	0.000644	0.0016	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—thyroid cancer	0.000643	0.0016	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—thyroid cancer	0.000642	0.0016	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000638	0.00159	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—HRAS—thyroid cancer	0.000626	0.00302	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000624	0.00155	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—TCF7L1—thyroid cancer	0.000623	0.003	CbGpPWpGaD
Olopatadine—Fatigue—Doxorubicin—thyroid cancer	0.000623	0.00155	CcSEcCtD
Olopatadine—Pain—Doxorubicin—thyroid cancer	0.000618	0.00154	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—thyroid cancer	0.000617	0.00153	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—thyroid cancer	0.000617	0.00153	CcSEcCtD
Olopatadine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000595	0.00148	CcSEcCtD
Olopatadine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000591	0.00147	CcSEcCtD
Olopatadine—Hypersensitivity—Epirubicin—thyroid cancer	0.000575	0.00143	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—thyroid cancer	0.000571	0.00142	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—thyroid cancer	0.000571	0.00142	CcSEcCtD
Olopatadine—Asthenia—Epirubicin—thyroid cancer	0.00056	0.00139	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—AKT1—thyroid cancer	0.000553	0.00266	CbGpPWpGaD
Olopatadine—Pruritus—Epirubicin—thyroid cancer	0.000552	0.00137	CcSEcCtD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000552	0.00266	CbGpPWpGaD
Olopatadine—Diarrhoea—Epirubicin—thyroid cancer	0.000534	0.00133	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000532	0.00132	CcSEcCtD
Olopatadine—Asthenia—Doxorubicin—thyroid cancer	0.000518	0.00129	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—thyroid cancer	0.000516	0.00128	CcSEcCtD
Olopatadine—HRH1—GPCR downstream signaling—CALCB—thyroid cancer	0.000513	0.00247	CbGpPWpGaD
Olopatadine—Pruritus—Doxorubicin—thyroid cancer	0.000511	0.00127	CcSEcCtD
Olopatadine—S100A12—Immune System—CDK1—thyroid cancer	0.000506	0.00243	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000506	0.00243	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000505	0.00243	CbGpPWpGaD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000503	0.00242	CbGpPWpGaD
Olopatadine—Vomiting—Epirubicin—thyroid cancer	0.000496	0.00123	CcSEcCtD
Olopatadine—Diarrhoea—Doxorubicin—thyroid cancer	0.000494	0.00123	CcSEcCtD
Olopatadine—Rash—Epirubicin—thyroid cancer	0.000492	0.00122	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—thyroid cancer	0.000492	0.00122	CcSEcCtD
Olopatadine—Headache—Epirubicin—thyroid cancer	0.000489	0.00122	CcSEcCtD
Olopatadine—S100A12—Immune System—IFNA2—thyroid cancer	0.000486	0.00234	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDK1—thyroid cancer	0.000478	0.0023	CbGpPWpGaD
Olopatadine—Dizziness—Doxorubicin—thyroid cancer	0.000478	0.00119	CcSEcCtD
Olopatadine—HRH1—Signaling by GPCR—CALCB—thyroid cancer	0.000466	0.00224	CbGpPWpGaD
Olopatadine—Nausea—Epirubicin—thyroid cancer	0.000464	0.00115	CcSEcCtD
Olopatadine—S100B—Immune System—IFNA2—thyroid cancer	0.00046	0.00221	CbGpPWpGaD
Olopatadine—Vomiting—Doxorubicin—thyroid cancer	0.000459	0.00114	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—TSHR—thyroid cancer	0.000456	0.0022	CbGpPWpGaD
Olopatadine—Rash—Doxorubicin—thyroid cancer	0.000456	0.00113	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—thyroid cancer	0.000455	0.00113	CcSEcCtD
Olopatadine—Headache—Doxorubicin—thyroid cancer	0.000453	0.00113	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000449	0.00216	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000429	0.00207	CbGpPWpGaD
Olopatadine—Nausea—Doxorubicin—thyroid cancer	0.000429	0.00107	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—MEN1—thyroid cancer	0.000429	0.00207	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—TSHR—thyroid cancer	0.00042	0.00202	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00041	0.00197	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NRG1—thyroid cancer	0.000406	0.00195	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTCH1—thyroid cancer	0.000388	0.00187	CbGpPWpGaD
Olopatadine—S100B—Immune System—NRG1—thyroid cancer	0.000384	0.00185	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—PTCH1—thyroid cancer	0.000357	0.00172	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SST—thyroid cancer	0.000355	0.00171	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—AKT1—thyroid cancer	0.000353	0.0017	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PTEN—thyroid cancer	0.000349	0.00168	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CALCA—thyroid cancer	0.000342	0.00164	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PTEN—thyroid cancer	0.00033	0.00159	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—SST—thyroid cancer	0.000327	0.00157	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CALCA—thyroid cancer	0.000315	0.00151	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NRAS—thyroid cancer	0.000311	0.0015	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDK1—thyroid cancer	0.000309	0.00149	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—NRAS—thyroid cancer	0.000295	0.00142	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CALCB—thyroid cancer	0.000275	0.00133	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—KRAS—thyroid cancer	0.000268	0.00129	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TRIM33—thyroid cancer	0.000261	0.00126	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—KRAS—thyroid cancer	0.000253	0.00122	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NRG1—thyroid cancer	0.000248	0.00119	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—TSHR—thyroid cancer	0.000238	0.00114	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HRAS—thyroid cancer	0.000228	0.0011	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TERT—thyroid cancer	0.000223	0.00107	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000218	0.00105	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—TSHR—thyroid cancer	0.000216	0.00104	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HRAS—thyroid cancer	0.000215	0.00104	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HIF1A—thyroid cancer	0.000213	0.00103	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000212	0.00102	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PTEN—thyroid cancer	0.000203	0.000979	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—AKT1—thyroid cancer	0.000201	0.000969	CbGpPWpGaD
Olopatadine—S100B—Immune System—PTEN—thyroid cancer	0.000192	0.000926	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—AKT1—thyroid cancer	0.00019	0.000916	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—SST—thyroid cancer	0.000185	0.000889	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PTCH1—thyroid cancer	0.000183	0.000883	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NRAS—thyroid cancer	0.000181	0.000873	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000181	0.000872	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CALCA—thyroid cancer	0.000178	0.000856	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—BRAF—thyroid cancer	0.000176	0.00085	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TCF7L1—thyroid cancer	0.000174	0.000838	CbGpPWpGaD
Olopatadine—S100B—Immune System—NRAS—thyroid cancer	0.000172	0.000826	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—SST—thyroid cancer	0.000168	0.000808	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CALCA—thyroid cancer	0.000161	0.000777	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.00016	0.00077	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KRAS—thyroid cancer	0.000156	0.000752	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000156	0.000751	CbGpPWpGaD
Olopatadine—S100B—Immune System—KRAS—thyroid cancer	0.000148	0.000711	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CDK1—thyroid cancer	0.000146	0.000704	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000136	0.000655	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HRAS—thyroid cancer	0.000133	0.000639	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000133	0.000638	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCND1—thyroid cancer	0.000129	0.00062	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000128	0.000616	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TSHR—thyroid cancer	0.000127	0.000613	CbGpPWpGaD
Olopatadine—S100B—Immune System—HRAS—thyroid cancer	0.000125	0.000604	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000125	0.000604	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTEN—thyroid cancer	0.000124	0.000598	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MEN1—thyroid cancer	0.00012	0.000577	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—thyroid cancer	0.000117	0.000564	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NRAS—thyroid cancer	0.000111	0.000534	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—thyroid cancer	0.000111	0.000533	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTCH1—thyroid cancer	0.000108	0.000522	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000103	0.000496	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SST—thyroid cancer	9.91e-05	0.000477	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KRAS—thyroid cancer	9.55e-05	0.00046	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CALCA—thyroid cancer	9.54e-05	0.000459	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDK1—thyroid cancer	8.63e-05	0.000416	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—thyroid cancer	8.48e-05	0.000408	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HRAS—thyroid cancer	8.11e-05	0.000391	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—thyroid cancer	7.16e-05	0.000345	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRG1—thyroid cancer	6.93e-05	0.000334	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TERT—thyroid cancer	6.22e-05	0.0003	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HIF1A—thyroid cancer	5.95e-05	0.000287	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TPR—thyroid cancer	5.92e-05	0.000285	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.82e-05	0.00028	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—NRAS—thyroid cancer	5.24e-05	0.000252	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—BRAF—thyroid cancer	4.93e-05	0.000237	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KRAS—thyroid cancer	4.51e-05	0.000217	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.43e-05	0.000213	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—HRAS—thyroid cancer	3.84e-05	0.000185	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	3.73e-05	0.00018	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—RXRA—thyroid cancer	3.72e-05	0.000179	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCND1—thyroid cancer	3.6e-05	0.000173	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTEN—thyroid cancer	3.47e-05	0.000167	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—thyroid cancer	3.39e-05	0.000163	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRAS—thyroid cancer	3.1e-05	0.000149	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KRAS—thyroid cancer	2.67e-05	0.000128	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—thyroid cancer	2.37e-05	0.000114	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPARG—thyroid cancer	2.35e-05	0.000113	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HRAS—thyroid cancer	2.27e-05	0.000109	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—thyroid cancer	2e-05	9.63e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.85e-05	8.9e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTEN—thyroid cancer	1.61e-05	7.76e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—thyroid cancer	9.29e-06	4.47e-05	CbGpPWpGaD
